类风湿关节炎缓解或低疾病活动度患者:TNF抑制剂拉长间期或甲氨蝶呤减量对比持续治疗的随机对照试验(SORAIRO试验)
SORAIRO试验为多中心开放标签随机非劣效性研究,纳入前序ozoralizumab III期试验中基于CDAI处于缓解或低疾病活动度的类风湿关节炎患者,随机分为持续治疗、ozoralizumab拉长间期或甲氨蝶呤减量组,主要终点为48周低疾病活动度维持的非劣效性(非劣效界值-18%)。共分析144例患者,48周低疾病活动度维持率持续治疗组97.9%,ozoralizumab拉长间期组79.2%(差值-21.6,95%CI -39.9至-5.7),甲氨蝶呤减量组72.7%(差值-30.4,95%CI -54.0至-10.5),均未达到非劣效;基线缓解亚组三组缓解维持率相当(77.4%、76.7%、79.2%)。结论提示低疾病活动度患者减量治疗可能不可行,而缓解患者延长TNF抑制剂间期或减少甲氨蝶呤剂量可能是合理选择。
要点
- 低疾病活动度患者中,TNF抑制剂拉长间期或甲氨蝶呤减量均未达到非劣效于持续治疗。
- 基线缓解亚组三组48周缓解维持率相当(77.4%、76.7%、79.2%)。
- 各组HAQ-DI和mTSS变化无显著差异,不良事件发生率分别为68.0%、59.2%、58.0%。
核心结论
- 低疾病活动度患者减量治疗可能不可行,而缓解患者延长TNF抑制剂间期或减少甲氨蝶呤剂量可能是合理选择。
研究设计与样本
- SORAIRO试验为多中心、开放标签、随机、非劣效性研究,纳入前序ozoralizumab III期试验中基于CDAI处于缓解或低疾病活动度的类风湿关节炎患者,预设样本量141例,实际分析144例。
主要发现
- 48周低疾病活动度维持率:持续治疗组97.9%,ozoralizumab拉长间期组79.2%(差值-21.6,95%CI -39.9至-5.7),甲氨蝶呤减量组72.7%(差值-30.4,95%CI -54.0至-10.5)。
- 基线缓解亚组48周缓解维持率:持续治疗组77.4%,ozoralizumab拉长间期组76.7%,甲氨蝶呤减量组79.2%。
- HAQ-DI和mTSS变化三组间无显著差异;不良事件发生率分别为68.0%、59.2%、58.0%。
关键数值与推荐
- 主要终点为48周低疾病活动度维持的非劣效性,预设非劣效界值为-18%。
- 患者平均年龄58.2岁,女性占75.0%,平均CDAI为2.70,61.8%处于缓解。
临床怎么用
- 对处于缓解的类风湿关节炎患者,可考虑延长TNF抑制剂给药间期或减少甲氨蝶呤剂量。
- 对仅达低疾病活动度而未缓解的患者,不建议减量治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to assess the noninferiority of spacing a tumour necrosis factor (TNF) inhibitor or reducing the methotrexate dose with continued treatment in patients with rheumatoid arthritis. METHODS: The SORAIRO trial was a multicentre, open-label, randomised, noninferiority study. Patients who had been in remission or low disease activity based on the Clinical Disease Activity Index (CDAI) in the preceding phase III trial of ozoralizumab, a next-generation TNF inhibitor, were enrolled. The precalculated sample size was 141. Patients were randomised into continued treatment, ozoralizumab spacing, or methotrexate dose reduction groups. The primary endpoint was a noninferiority of low disease activity maintenance at week 48 with a prespecified noninferiority margin of -18%. RESULTS: A total of 144 patients were analysed. The mean age was 58.2 years, 75.0% were female, and the mean CDAI was 2.70 with 61.8% in remission. The low disease activity at week 48 was 97.9% in the continued treatment group, 79.2% in the ozoralizumab spacing group (difference, -21.6; 95% CI, -39.9 to -5.7), and 72.7% in the methotrexate dose reduction group (difference, -30.4; 95% CI, -54.0 to -10.5). In the baseline remission subgroup, remission maintenance rates were comparable in the 3 groups (77.4%, 76.7%, 79.2%, respectively). No significant differences were demonstrated in changes in the Health Assessment Questionnaire Disability Index and modified total Sharp score. Adverse events occurred in 68.0%, 59.2%, and 58.0%, respectively. CONCLUSIONS: Treatment tapering may not be feasible in patients with low disease activity, whereas both extending the TNF inhibitor interval and reducing the methotrexate dose may be reasonable options for patients in remission.
引用
- Imai Y, Kono M, Ishii T, et al. Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial). Ann Rheum Dis. 2026. PMID: 41763966. doi:10.1016/j.ard.2026.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。